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Purpose: The main objective of this study was to develop a novel aerosolized liposome 
  formulation for pulmonary delivery of anti-asthmatic medication and to explore the relationship 
between the bioavailability and anti-asthmatic efficacy of such a formulation. Asthma treatment 
usually requires frequent administration of medication for sustained bronchodilating response. 
Liposomes are known for their capability for sustained drug release and thus would be a suitable 
delivery system for anti-asthmatic medication for prolonged therapeutic effect. Salbutamol 
sulfate (SBS) was chosen as the model drug in this study because of its high water solubility 
and fast absorption after administration.
Methods: SBS was efficiently encapsulated into liposomes by the vesicular phospholipid gel 
technique. SBS permeability across the pulmonary membrane of an Asian toad was determined 
by in vitro study. Intratracheal administration of liposomes labeled with the fluorescent dye 
1,1′-dioctadecyltetramethyl indotricarbocyanine iodide (DiR) in a rat model was assessed by a 
small animal imaging system and pharmacokinetic analysis. Pharmacodynamic analysis was 
performed in guinea pigs using the Konzett–Rössler method.
Results: SBS was efficiently encapsulated into liposomes with encapsulation efficiency as high 
as 70%. The particle size of the SBS liposome suspension was approximately 57 ± 21 nm. In 
the in vitro study of permeability across the pulmonary membrane of Asian toads, SBS from 
liposomes demonstrated a slower transport rate compared to free SBS solution. Pulmonary 
delivery of liposomes in a rat model showed that the liposomes were effectively distributed in 
the respiratory tract and lungs, and that the release of SBS from liposomes was sustained for at 
least 48 hours. Pharmacodynamic analysis in a guinea pig model showed that the anti-asthmatic 
effect of SBS liposomes persisted for up to 18 hours, whereas that of free SBS solution was 
less than 8 hours.
Conclusion: The overall results demonstrated that liposomes could increase the concentration 
and retention time of SBS in the lungs and therefore prolong its therapeutic effect.
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Introduction
Asthma is a chronic pulmonary disease that has recently been rising in incidence in 
adults.1 The first selective β2 receptor agonist salbutamol sulfate (SBS) has been widely 
used for the treatment of bronchospasm in conditions such as exercise-induced asthma2 
and chronic obstructive pulmonary disease.3 Commercial pharmaceutical formulations 
of SBS include aerosols, injection fluids, mixtures, and tablets.4 While effective, oral 
or intravenous administration of SBS in high doses is often associated with adverse 
effects, including maternal and fetal tachycardia, maternal hyperglycemia, dyspnea, 
palpitations, anxiety, and oliguria.5 Moreover, SBS is subject to first-pass elimination 
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in the liver when it is taken orally.6 As a result, SBS is now 
rarely delivered via the oral route and is usually given by 
inhalation. Pulmonary delivery stands out among alternative 
administration routes because of the direct targeting of drugs 
to the lungs, which reduces unwanted systemic activity or 
toxicity. Conventional SBS aerosol formulations demonstrate 
a fast pharmacokinetic profile and thus the dosage must be 
repeated every 4–6 hours to sustain a bronchodilating 
response.7 Accordingly, a novel SBS dosage form with a 
long-lasting effect is desperately needed to treat asthma.
To convey a sufficient dose of drug to the lungs, suitable 
drug carriers are required. These can be either liquid,8–14 
solid,14,15 or gaseous formulations. Over the years, liposomes 
have received widespread attention as a pulmonary drug 
delivery system,8,16 providing an attractive means for nonin-
vasive delivery and sustained release of drugs for treating 
chronic diseases, such as asthma and diabetes.   Liposome- 
mediated pulmonary drug delivery may increase drug retention 
time in the lungs while reducing extrapulmonary side effects, 
resulting in enhanced therapeutic efficacy.17
The use of liposomes for topical administration may 
retain and localize SBS within a reservoir at the site of 
administration. Thus, liposome formulations with high SBS 
carrying capacities and improved retention times are desired. 
In this study, an aerosolized liposome carrier for pulmonary 
delivery of SBS was developed. The drug was encapsulated 
into liposomes by the vesicular phospholipid gel (VPG) 
technique. The encapsulation efficiency (EE) and particle 
size of liposomes were optimized. The in vitro permeability 
of SBS liposome formulation across Asian toad pulmonary 
membrane was compared to that of free SBS solution. The 
distribution and elimination of liposomal SBS in the lungs 
and its pharmacokinetic and pharmacodynamic parameters 
were studied in animal models via direct pulmonary 
administration.
Materials and methods
Materials
SBS was purchased from Changzhou Yabang Pharmaceutical 
Co, Ltd (Changzhou, China). Soybean phosphatidylcholine 
(SPC) was purchased from Taiwei Pharmaceutical Co, Ltd 
(Shanghai, China). The isotonic agents used in this study 
were glucose (Riedelde Haën, Seelze, Germany), α-lactose 
monohydrate (Sigma Aldrich, St Louis, MO), mannitol 
(International Laboratory, San Bruno, CA), and trehalose 
(International Laboratory). Acetonitrile (HPLC grade) was 
supplied by Labscan Asia Co, Ltd (Bangkok, Thailand). 
Deionized water was generated by a Milli Q ultrapure water 
system (Millipore, Billerica, MA). Ethanol (Labscan Asia 
Co, Ltd) was of analytical grade. 1,1′-dioctadecyltetramethyl 
indotricarbocyanine iodide (XenoLight DiR) was obtained 
from Caliper LifeSciences (Hopkinton, MA). Histamine was 
purchased from Sigma Aldrich.
Animals
Male Sprague Dawley rats with an average weight of 
220 ± 20 g and male guinea pigs with an average weight of 
480 ± 30 g were used (Laboratory Animal Services Center, 
The Chinese University of Hong Kong). All procedures 
involving animals were carried out according to the guide-
lines of the Committee on the Use of Human and Animal 
Subjects in Teaching and Research of Hong Kong Baptist 
University and the Health Department of Hong Kong Special 
Administrative Region.
Methods
Preparation and dilution of SBS VPg  
and SBS DiR VPg
The preparation of VPG was conducted based on the protocol 
described by Brandl and Massing.18 For production of SBS 
VPG (40% of SPC and 8.3% of SBS by mass), SPC was 
dispersed in 10 mL of aqueous SBS solution (13.9% of SBS 
by mass) by manual shaking in a stoppered tube for over 
2 minutes. After incubation in a water bath at 60°C for 
2 hours, the mixture was stirred using a homogenizer (Ultra 
Turrax T18; IKA, Staufen, Germany) for 5 minutes to form 
a semisolid homogenous product. SBS-VPG was formed by 
incubation in a water bath at 60°C for 12 hours and was 
stored at 4°C before use. SBS liposome suspension (4 mg/mL) 
was prepared by diluting 0.48 g of SBS VPG with 10 mL of 
α-lactose solution (77 mg/mL). The same procedures were 
applied for the production of SBS DiR VPG (40% of SPC 
and 8.3% of SBS by mass), except that SPC was dispersed 
in aqueous SBS solution containing 200 µL of DiR ethanol 
solution (8.33 mg DiR/mL) and then SBS DiR VPG was 
stored and protected from light at -20°C before use.
Characterization of liposome SBS
The particle size distribution of the liposomes was determined 
by using the DELSA 440SX Zeta Potential Analyzer (Beckman 
Coulter, Brea, CA). Measurement was made at 25°C.
The EE of SBS in the liposomes was determined by the 
Microcon method.19,20 Briefly, an aliquot of the liposome 
suspension (200 µL) was added to the sample reservoir of a 
Microcon centrifugal filter device containing an ultrafiltration 
membrane (NMWL 10000, Millipore) and centrifuged 
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(Avanti® J-E, Beckman Coulter) at 17400g for 15 minutes 
at 4°C. 50 µL of filtrate was diluted with 1450 µL of 80% 
ethanol and assayed to determine the concentration of the 
unencapsulated SBS by a UV spectrophotometer (Cary 50 
Tablet; Varian Technologies Asia Ltd, Taipei, Taiwan) at 
276 nm. To determine the total SBS concentration, the lipo-
some structure was destroyed by adding 1450 µL of 80% 
ethanol to 50 µL of the original liposome suspension. EE was 
calculated by the following formula:
EE = [(Total drug – Unencapsulated drug)/Total drug] × 100% 
   =  (CsVs – CfVf)/CsVs × 100% ≈ (Cs – Cf)/Cs × 100%
in which Cs and Cf are the SBS concentrations in the original 
liposome suspension and filtrate, respectively, whereas Vs 
and Vf are the volumes of the original liposome suspension 
and filtrate, respectively. Vf can be approximated to Vs 
because Vf = Vs – Vl where Vl represents the volume of the 
liposome vesicles and Vl was less than 5% of Vs.
Transport of SBS across pulmonary membrane
SBS permeability across the pulmonary membrane of an 
Asian toad (an amphibian similar to Xenopus) was deter-
mined according to the method previously reported by other 
groups.21–23 The toad was anesthetized by ether and then 
underwent ventral incision to expose the thoracic cavity. The 
lungs were excised by severing the tracheoglottis and washed 
with Ringer’s solution (110 mmol/L NaCl, 2.4 mmol/L 
NaHCO3, 2.4 mmol/L KCl, 1 mmol/L CaCl2, 5.5 mmol/L 
glucose, pH 7.4). After that, the lungs were cut open along 
the pulmonary artery to obtain a sheet membrane, both sides 
of which were gently washed with Ringer’s solution. The 
sheet membrane was mounted onto a horizontal diffusion 
cell (PermeGear, Inc, Hellertown, PA). The volume of both 
the donor chamber and acceptor chamber was 6 mL. The 
temperature of the chambers was maintained at 37°C. SBS 
liposome suspension (3 mL) or free SBS solution (3 mL) of 
the same concentration was mixed with 3 mL of Ringer’s 
solution and added to the donor chamber. Another 6 mL of 
Ringer’s solution was directly added to the acceptor chamber. 
The solutions in both chambers were stirred with a magnetic 
stirrer to maintain homogeneity. To determine the initial SBS 
concentration, 50 µL was withdrawn from the donor chamber 
immediately after SBS liposome suspension or free SBS 
solution was added; the SBS solution aliquot was diluted 
100-fold with deionized water for further assay, whereas the 
SBS liposome aliquot was first diluted five-fold with 80% 
ethanol to destroy the liposome structure and then further 
diluted 20-fold with deionized water. Afterwards, 1 mL of 
solution was withdrawn once every 15 minutes from the 
acceptor chamber for a period of 4 hours, and an equal vol-
ume of fresh Ringer’s solution was added to refill the chamber 
each time. The electrical resistance of the pulmonary mem-
brane was monitored (EVOM System; World Precision 
Instruments, Inc, Sarasota, FL) to ensure its integrity during 
the experiment. Each aliquot of withdrawn solution was 
filtered with a 0.45 µm membrane filter (Disposable Sterile 
Syringe Filters, Cellulose Acetate Membrane; Asahi Glass 
Co, Ltd, Tokyo, Japan), and then 400 µL of the filtrate was 
injected into the HPLC (Agilent 1100, Santa Clara, CA) to 
determine the amount of SBS that had crossed the mem-
brane at each time point. HPLC analysis was performed 
with the C18 column (250 × 4.60 mm; Phenomenex, 
  Torrance, CA) at 40°C and the UV detector at 276 nm. The 
injection volume was 20 µL. The mobile phase was a mix-
ture of acetonitrile and sodium dihydrogen phosphate buffer 
(0.03 M) in a ratio of 10:90 (V:V) with the addition of 1 M 
phosphoric acid solution to obtain a pH of 3.5, and the flow 
rate was 1 mL/minute.
In vivo animal studies
In vivo fluorescence imaging of DiR liposome  
distribution in rat lungs
Twenty-seven male Sprague Dawley rats were fasted for 
12 hours before the experiment. Rats were weighed and then 
anesthetized by intraperitoneal administration of 7% chloral 
hydrate at a dosage of 0.5 mL per 100 g of body weight. DiR 
SBS liposome suspension was administered directly via spray 
instillation to the lungs using a spray instillator (Model 
1A-1B MicroSprayer®; Penn Century, Wyndmoor, PA) at a 
dosage of 2 mg SBS/kg. At 15 minutes and 1, 2, 4, 8, 12, 18, 
24, and 48 hours (n = 3 for each time point) after drug admin-
istration, rats were sacrificed and the thoracic cavity was 
opened. The DiR SBS liposome distribution in rat lungs was 
assessed at each time point using a small animal imaging 
system (IVIS® Lumina XR; Caliper LifeSciences) with Liv-
ing Image software (v 4.0; Caliper LifeSciences).
Pharmacokinetic analysis in rat plasma
Ten Sprague Dawley rats were randomly divided into two 
groups and fasted for 12 hours before the experiment. Rats 
were weighed and then anesthetized by intraperitoneal admin-
istration of 7% chloral hydrate at a dosage of 0.5 mL per 100 g 
of body weight. SBS liposome suspension or free SBS solution 
was delivered intratracheally using the spray instillator at a 
dosage of 2 mg SBS/kg (n = 5 per group). Blood samples 
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(0.4 mL) were collected from the end of rat tails into, 
1000 IU/mL heparinized centrifuge tubes at 5 minutes and 
0.5, 1, 2, 3, 5, 7, 12, 24, and 48 hours after drug administration. 
Each sample was centrifuged at 1485g for 10 minutes at 4°C 
to separate the plasma from the blood cells. One hundred micro-
liters of plasma was mixed with 800 µL of acetonitrile by 
vortex for 3 minutes. The denatured protein precipitate was 
then separated by centrifugation at 13,362g for 10 minutes at 
4°C. The supernatant was transferred into a new centrifuge 
tube and the organic solvent was removed by vacuum at 25°C 
for 6 hours. The resulting residue was dissolved in 100 µL of 
deionized water with 0.1% formic acid by vortex for 2 minutes. 
The solution was then centrifuged at 13,362g for 10 minutes 
at 4°C. Fifty microliters of the supernatant was withdrawn 
for SBS determination using UPLC MS/MS analysis.
Concentration and disposition of SBS in rat lungs
Fifty-four Sprague Dawley rats were randomly divided into 
two groups and fasted for 12 hours before the experiment. Rats 
were weighed and then anesthetized by intraperitoneal admin-
istration of 7% chloral hydrate at a dosage of 0.5 mL per 100 g 
of body weight. SBS liposome suspension or free SBS solution 
was delivered intratracheally using the spray instillator at a 
dosage of 2 mg SBS/kg. At 15 minutes and 1, 2, 4, 8, 12, 18, 
24, 48 hours after drug administration (n = 3 for each time 
point), each animal was sacrificed for dissection of the lungs. 
Lung tissue samples were weighed and homogenized in 2 mL 
of physiological saline. The homogenate was then mixed 
with 12 mL of acetonitrile by vortex for 3   minutes. The dena-
tured protein precipitate was then separated by centrifugation 
at 30,966g for 15 minutes at 4°C. The supernatant was trans-
ferred into a new centrifuge tube and the organic solvent 
was removed by vacuum at 25°C for 12 hours. The resulting 
residue was dissolved in 3 mL of deionized water with 0.1% 
formic acid by vortex for 2   minutes. The solution was then 
filtered by a cellulose acetate membrane filter (0.2 µm, 
Grace Davison Discovery Sciences, Augusta, GA). One mil-
liter of the filtrate was withdrawn for SBS determination 
using UPLC-MS/MS analysis as stated below.
Pharmacodynamic study of guinea pigs
Pharmacodynamic analysis was performed in guinea pigs 
using the Konzett–Rössler method.24 The advantage of this 
method is that not only the bronchodilator activity but also 
the systemic influences, such as cardiovascular events, due 
to SBS can be monitored simultaneously in an animal 
  model.25 Briefly, each guinea pig was put into a plastic box 
(4.5 L) and then 0.4% histamine saline solution was sprayed 
into the box for 20 seconds at the rate of 70 L/minute. Asthma 
latent period is defined as the time it takes for the animal to 
twitch and fall down after spraying of histamine.26 Guinea 
pigs with an asthma latent period exceeding 120 seconds 
were not included in this study.
Selected guinea pigs were randomly divided into three 
groups with six in each group. Each guinea pig was weighed 
and then anesthetized by intraperitoneal administration of 
10% chloral hydrate at a dosage of 4 mL per kg of body 
weight. Each group of guinea pigs received SBS liposome 
suspension, free SBS solution, or saline blank solution 
through intratracheal delivery using the spray instillator at a 
dosage of 2 mg SBS/kg. At 2, 4, 6, 8, 12, 18, and 24 hours 
after drug administration, each animal was subject to the 
Konzett–Rössler experiment as described above. The asthma 
latent periods were recorded at each time point.
UPLC-MS/MS analysis
The analysis of SBS levels in vivo was carried out using 
UPLC (Acquity Ultra Performance Liquid Chromatography; 
Waters, Milford, MA) and MS/MS (MicroTOF-Q; Bruker 
Daltonics Inc, Billerica, MA), with the C18 column (1.7 µm, 
2.1 × 100 mm, Waters) at 40°C. The mobile phase was 0.1% 
formic acid in deionized water, with a flow rate of 
0.2 mL/minute. Ten microliters of the sample was used for 
the UPLC MS/MS analysis. SBS showed mass to electric 
charge ratio values of 148 and 166 in MS spectra.
Data analysis
The pharmacokinetic parameters were calculated and sum-
marized by Thermo Kinetica (v 5.0; Cypress Software Inc, 
Langley, WA).
All data were analyzed using SPSS software (v 11.0; IBM 
Corp, Armonk, NY). Data were presented as mean ± standard 
deviation (SD) and evaluated by Student’s t-test to analyze 
the differences in pharmacokinetic parameters between two 
groups and by ANOVA test to analyze the differences in EE 
and asthma latent period when there were more than two 
groups; P values below 0.05 indicate that the differences are 
statistically significant.
Results and discussion
Preparation of SBS VPg and SBS DiR VPg
VPG are semisolid matrices of densely packed liposomes, 
mainly consisting of small unilamellar vesicles, with high 
EE.27,28 VPG can be transformed into a “conventional” small-
sized liposome dispersion by the addition of excess aqueous 
medium and gentle mechanical agitation shortly before use. 
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During this dilution process, if appropriate conditions are 
maintained, the preformed vesicles in VPG would remain 
intact and retain their drug load.19 This has been confirmed 
by the present study using VPG to develop a liposomal carrier 
system for SBS. The particle sizes of SBS liposomes that 
were formed by dispersion of VPG were shown to range from 
33 to 58 nm (Table 1). VPG-derived liposome formulations 
contain high lipid content contributing to a considerably 
increased ratio of aqueous volume inside the vesicles to the 
surrounding aqueous volume and thus are suitable for entrap-
ping water-soluble substances with high EE (.50%).29 In 
addition, use of formulations with high EE has the benefit 
that there is no need to remove the unencapsulated drug 
before use, making the production process more efficient.30–32 
In order to investigate the effect of SPC content on the EE 
of VPG liposomes for SBS, a series of liposome dispersions 
were prepared with increasing SPC/VPG from 250 to 
500 mg/g. The EE was determined as the ratio of SBS con-
centration in the vesicle core to that in the total liposome 
suspension. As shown in Table 1, the EE was increased by 
increasing the SPC content in the original VPG (P , 0.05), 
suggesting that an increase of SPC/VPG (from 250 to 
400 mg/g) could lead to a higher volume of the vesicle core. 
However, it should also be noted that there was little increase 
in EE when SPC/VPG was above 400 mg/g. Complete hydra-
tion of phosphatidylcholine would require a water-to-lipid 
ratio higher than 45:55.18 In this study’s VPG formulation, 
the water-to-lipid ratio was 60:40 and 50:50 when SPC/VPG 
was 400 and 500 mg/g, respectively. At 500 mg/g, there was 
enough water present to completely hydrate the SPC lipid, 
but not enough to increase the aqueous core within the lipid 
vesicles. Thus, there was only a slight increase in the EE 
when SPC/VPG rose from 400 to 500 mg/g. For the subse-
quent studies, an SPC concentration of 400 mg/g was used 
to prepare SBS liposomes.
Incorporation of DiR into liposomes was investigated in 
two separate experiments. DiR liposome suspension, which 
was prepared by hydrating the DiR VPG (SPC 400 mg/g), 
was added into the Microcon centrifugal filter device and 
centrifuged at 17,400g for 15 minutes at 4°C. Fifty micro-
liters of filtrate was diluted with 1450 µL of 80% ethanol 
and the unencapsulated DiR was analyzed by a fluorospec-
trophotometer (LS 55 Luminescence Spectrometer, 
  PerkinElmer, Waltham, MA) at an excitation wavelength of 
748 nm and an emission wavelength of 780 nm. The filtrate 
showed no fluorescent intensity. In another experiment where 
liposome suspension was subject to extrusion through a 200-
nm polycarbonate membrane, there was no change of fluo-
rescent intensity in the suspension before or after   extrusion. 
These results indicated that DiR was not present in the aqueous 
phase of the suspension but mostly encapsulated into the lipid 
bilayer; this is in agreement with the lipophilic property of 
DiR. It has been reported that the two 18 carbon chains of DiR 
could insert into the liposome membrane, resulting in specific 
and stable liposome staining, with negligible dye transfer 
between liposomes and tissue cells.33
Effect of isotonic agents on the EE  
of SBS in liposomes
To further increase the EE of SBS in liposomes, the VPG 
with 400 mg/g SPC was hydrated with solutions of isotonic 
agents to prevent the release of SBS from the vesicles during 
conversion of the VPG into liposome suspension. The EE of 
SBS in liposomes reached 70.71% ± 1.55% when hydrated 
with lactose solution. This EE value was found to be higher 
than that of the liposome suspension hydrated by deionized 
water (57.11% ± 0.11%) or by other isotonic solutions 
(Table 2, P , 0.05). As the mass ratio of SBS (molar 
mass = 576.7 g/mol) in the VPG formulation was 8.3%, the 
molar concentration of SBS in the aqueous phase of the VPG 
was calculated to be 0.28 M, and one molecule of SBS may 
dissociate into different ions in the aqueous solution. It can 
be inferred that the dispersion medium for VPG should be 
near isotonic to the aqueous phase within the vesicles. 
  Isotonic agents could adjust the osmotic pressures in the inner 
and outer aqueous phases of vesicles to prevent the leakage 
of water-soluble SBS from the core of these vesicles when 
VPG is dispersed to form liposome suspension. The structure 
of lipid vesicles may also be changed by many other factors, 
such as the solubility of the isotonic agent and viscosity of 
the dispersion medium. Isotonic agents used in this study 
have different solubilities in water; the solubilities of glucose, 
mannitol, trehalose, and lactose at room temperature are 91, 
22, 69, and 19 g in 100 mL of water, respectively. Other 
physical and chemical properties of isotonic agents may also 
affect their interaction with lipids and thus the EE of 
Table 1 Effect of SPC content in VPg on the liposome particle sizes 
and the EE of SBS in the liposome suspension (mean ± SD, n = 3)
SPC/VPG (mg/g) EE%a Particle size (nm)
250 35.12 ± 0.99 33 ± 5.0
300 40.47 ± 0.14 47 ± 10
400 57.11 ± 0.11 57 ± 21
500 58.92 ± 0.07 58 ± 26
Note: aP , 0.05 for comparison between any two groups using ANOVA test.
Abbreviations: EE, encapsulation efficiency; SBS, salbutamol sulfate; SD, standard 
deviation; SPC, soybean phosphatidylcholine; VPG, vesicular phospholipid gel.
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Table 2 Optimization of EE (mean ± SD, n = 3) of SBS in VPg 
liposomes by hydration with different concentrations of isotonic 
agents
Isotonic  
agent
Concentration EE (%)
mg/mL M
glucose 19.2 0.11 60.32 ± 0.37
38.4 0.21 61.52 ± 0.11
50.4 0.28 63.99 ± 0.64
76.8 0.43 65.75 ± 0.46
115.2 0.64 66.29 ± 1.57
Mannitol 19.2 0.11 65.27 ± 0.60
38.4 0.21 62.53 ± 0.81
50.4 0.28 62.45 ± 0.87
76.8 0.43 65.60 ± 0.56
115.2 0.64 63.22 ± 1.20
Trehalose 19.2 0.06 61.09 ± 0.15
38.4 0.11 61.95 ± 0.69
76.8 0.22 60.71 ± 0.65
95.8 0.28 64.50 ± 0.75
115.2 0.34 65.27 ± 0.60
Lactose 19.2 0.06 60.46 ± 3.01
38.4 0.11 63.70 ± 0.23
76.8 0.22 70.71 ± 1.55a
95.8 0.28 69.84 ± 0.77
115.2 0.34 67.03 ± 0.47
Notes: The SBS concentration used for preparation of VPg liposomes was 83.4 
mg/g.  The  average  molar  concentration  of  SBS  in  the  aqueous  phase  of  VPg 
was 0.28 M.  aP , 0.05 for comparison with other groups except for the molar 
concentration of lactose 0.28 M using analysis of variance test.
Abbreviations: EE, encapsulation efficiency; SBS, salbutamol sulfate; SD, standard 
deviation; VPG, vesicular phospholipid gel.
SBS in liposomes. This is reflected by the observation that 
the EE was not correlated with the concentration of isotonic 
agents. However, the study’s data suggest that the osmotic 
pressure of the dispersion medium could be one important 
factor for maintaining high EE in VPG-derived liposome 
formulations. In this study, the EE of SBS in liposomes was 
optimized by adjusting the molar ratio of lactose closely to 
the average concentration of SBS in the inner aqueous phase 
of lipid vesicles. It was confirmed that the presence of DiR 
did not significantly change the EE of SBS in liposomes with 
lactose hydration (EE = 68.22% ± 1.78%).
Effect of liposomes on the transport  
rate of SBS across the pulmonary 
membrane
Figure 1 shows the transport profiles of SBS across the pulmo-
nary membrane in vitro for comparison between the SBS 
liposome suspension and free SBS solution. SBS from liposome 
suspension displayed a relatively slower transport rate over the 
course of time when compared to free SBS solution.   Interactions 
between liposomes and cells of the pulmonary membrane may 
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Figure  1  Effect  of  liposomes  on  the  transport  rate  of  SBS  across  Asian  toad 
pulmonary membrane in vitro.
Notes: The concentrations of SBS in liposome suspension (•) and control solution 
(∆)  were  2.11  mg/mL  and  2.22  mg/mL,  respectively.  Data  were  expressed  as 
mean ± SD (n = 3).
Abbreviations: SBS, salbutamol sulfate; SD, standard deviation.
influence the release rate of SBS from   liposomes. A previous 
report has described how some liposomes could be incorpo-
rated into the pulmonary membrane.34–36 Therefore, it is likely 
that there could be other forces besides diffusion that drive 
the transport of encapsulated SBS across the pulmonary 
membrane. Since the liposome vesicle was much larger than 
the SBS molecule in size, it was estimated that the transport 
rate of SBS from liposomes should be at least a dozen times 
slower than that of free SBS molecules. However, this study 
demonstrated only about a two-fold decrease in the transport 
rate of SBS from liposomes after 4 hours (Figure 1). This could 
be explained by the possibility that some liposomes were dam-
aged, resulting in the release of entrapped SBS before interact-
ing with cells of the pulmonary membrane. Nonetheless, the 
data suggest that liposomes could slow down the migration of 
SBS across the pulmonary membrane and thus increase the 
relative bioavailability of SBS.
In vivo animal studies
In vivo fluorescence imaging of DiR-liposome 
distribution in rat lungs
In studies involving pulmonary drug administration, it is 
important to confirm whether the dosage has been effectively 
administered into the lungs. Real time in vivo fluorescence 
imaging is a very effective and widely applicable technology 
for studying drug deposition in tissues. Temporal and spatial 
data can be collected by labeling drugs with a fluorescent 
molecule such as a dye or quantum dot prior to administration 
into an animal model.37 In the present study, DiR, a near 
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infrared fluorescent cyanine dye, was used for staining the 
lipid membrane. After intratracheal administration of DiR 
liposomes using the spray instillator, rats were sacrificed to 
expose the thoracic cavity for better fluorescence imaging 
effect. Serial images of the lungs showed persistent disposi-
tion of DiR SBS liposomes through the tracheobronchial tree 
(Figure 2A). Of important note, DiR SBS liposomes were 
observed in rat lungs even at 48 hours after drug administra-
tion, suggesting that liposomes could remain in the lungs and 
release SBS to exert sustained therapeutic effect. In addition, 
the elimination rate constant of DiR incorporated in the 
bilayer of the liposome membrane was calculated in order 
to estimate the elimination rate of liposomes in rat lungs. As 
shown in Figure 2B, the total radiation efficiency of DiR in 
the respiratory tissues decreased with a first order rate 
  constant of 0.123 h-1.
Pharmacokinetic analysis in rat plasma
SBS is a typical water-soluble active pharmaceutical 
  ingredient. It has been reported that SBS can be absorbed to 
its maximum concentration as early as 10 minutes after 
administration,38 suggesting that SBS can be immediately 
absorbed into the circulation system once it is released from 
the liposome at the respiratory tract. In order to evaluate the 
sustained release effect of SBS liposome formulation in the 
lungs, the pharmacokinetics of SBS were analyzed by col-
lecting serial plasma samples from rats after intratracheal 
administration of SBS liposome suspension or free SBS 
solution (Table 3). The mean residence time for the SBS 
liposome group (18.73 ± 2.54 hours) was greater than that 
for the free SBS solution group (8.09 ± 2.65 hours) 
(P , 0.05), suggesting that entrapped SBS had remained in 
the pulmonary system longer. Figure 3 further reveals that 
liposomes significantly slowed the elimination of entrapped 
SBS from the lungs; the free SBS solution group showed a sig-
nificantly higher SBS concentration (1139.78 ± 180.61 ng/mL) 
in plasma at 5 minutes when compared to the SBS liposome 
suspension group (124.46 ± 84.64 ng/mL). These data sug-
gest that free or unencapsulated SBS could transport across 
alveolar membrane immediately but liposomes could prevent 
the release and transportation of entrapped SBS into the 
blood. There was no detectable SBS in plasma for the free 
SBS solution group after 24 hours, whereas an average con-
centration of 11.62 ± 5.13 ng/mL was still observed for the 
SBS liposome group at 48 hours (Figure 3), therefore imply-
ing that liposomal SBS was slowly released from the lungs. 
The pharmacokinetic findings suggest that liposome formula-
tions could maintain the localization of SBS in pulmonary 
tissues. The relationship between liposomal SBS remaining 
in pulmonary tissues and its anti-asthmatic effect was further 
investigated in the studies below.
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Figure 2B Decrease of fluorescence intensity of DiR SBS liposomes in rat lungs 
after intratracheal administration.
Note: n = 3 for each time point.
Abbreviations: SBS, salbutamol sulfate; DiR, 1,1′-dioctadecyltetramethyl indotri-
carbocyanine iodide.
Figure 2A Fluorescence imaging of DiR SBS liposome disposition in rat lungs at 
different time points after intratracheal administration.
Abbreviations: SBS, salbutamol sulfate; DiR, 1,1′-dioctadecyltetramethyl indotri-
carbocyanine lodide.
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Table 3 Pharmacokinetic analysis of SBS in the plasma of rats 
after pulmonary administration of SBS liposome formulation or 
free SBS solution
Parameters Liposome SBS Free SBS solution
AUC0-∞ (ng/mL × h) 1376.58 ± 598.22    1471 ± 733.88
MRT (h)a 18.73 ± 2.54     8.09 ± 2.65
Cmax
 (ng/mL) 168.45 ± 77.94 1139.78 ± 180.61
Tmax (h) 2.38 ± 0.89 –b
Notes: Data were expressed as mean ± SD (n = 5). aStudent’s t-test: liposome SBS 
versus free SBS solution, P , 0.05; bthere was no Tmax for free SBS solution.
Abbreviations: MRT, mean residence time; AUC0 h–∞, area under the curves from 
time zero to infinity; SBS, salbutamol sulfate; SD, standard deviation.
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Figure 3 SBS concentration in the plasma of rats at different time points after 
pulmonary administration of SBS liposome formulation or free SBS solution.
Note: Data were expressed as mean ± SD (n = 5).
Abbreviations: SBS, salbutamol sulfate; SD, standard deviation.
Table 4 Parameters of the various formulations of SBS in rat 
lungs after pulmonary administration (mean ± SD, n = 3)
Parameters Liposome SBS Free SBS solution
AUC0–∞ (µg/g × h)a 1061.37 ± 27.20a 173.05 ± 21.36
MRT (h)a 21.85 ± 1.41a 3.27 ± 0.07
Clearancea 6.39 ± 0.20a 44.31 ± 4.32
Notes: aStudent’s t-test: liposome SBS versus free SBS solution, P , 0.05.
Abbreviation: AUC0 h–∞, area under the curves from time zero to infinity; MRT, 
mean residence time; SBS, salbutamol sulfate; SD, standard deviation.
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Figure  4  SBS  concentration  in  the  lungs  of  rats  at  different  time  points  after 
pulmonary administration of SBS liposome formulation or free SBS solution.
Note: Data were expressed as mean ± SD (n = 3).
Abbreviations: SBS, salbutamol sulfate; SD, standard deviation.
Concentration and disposition of SBS in rat lungs
The sustained release profile of SBS liposomes was evaluated 
by measuring the SBS concentrations in the rat lungs at dif-
ferent time points after pulmonary administration of SBS 
liposomes. Appreciable increases in the mean residence time 
and area under the curves from time zero to infinity (AUC0 h–∞) 
of SBS remaining in pulmonary tissues were observed in rats 
administered with SBS liposome suspension (Table 4; 
P , 0.05). Particularly, the mean residence time of the SBS 
liposome group (21.85 ± 1.41 hours) was seven-fold longer 
compared  to  that  of  the  free  SBS  solution  group 
(3.27 ± 0.07 hours), whereas AUC0 h–∞ of the SBS liposome 
group (1061.37 ± 27.20 µg/g ⋅ h) was six-fold higher than 
that of the free SBS solution group (173.05 ± 21.36 µg/g ⋅ h). 
As shown in Figure 4, the free SBS solution group showed 
a significantly lower concentration of SBS in the lungs com-
pared to the SBS liposome group, suggesting that free SBS 
solution could travel across the alveolar membrane, quickly 
spreading into the circulation. During the first 12 hours after 
administration of the SBS liposome suspension, SBS 
  concentration in the lungs decreased in a first-order fashion 
with a rate constant of 0.291 h-1. In contrast, during the first 
8 hours after administration of free SBS solution, SBS con-
centration in the lungs decreased with a first-order rate 
constant of 0.519 h-1. These data indicated that the migration 
of SBS from the lungs to the plasma was nearly two-fold 
slower when it was delivered in liposome suspension. 
  Moreover, the elimination rate for SBS (0.291 h-1) was shown 
to be much faster than that of DiR (0.123 h-1), suggesting 
that pulmonary elimination of lipids may be half as fast as 
that of SBS. Liposome formulations could prevent the rapid 
release and elimination of SBS from the pulmonary tissues, 
resulting in a higher SBS concentration remaining in the 
lungs. These data implicate the potential use of liposomes 
for prolonging the anti-asthmatic effect of SBS.
Pharmacodynamic study of guinea pigs
To investigate the anti-asthmatic effect of SBS liposomes, 
pharmacodynamic analysis was performed using the 
Konzett–Rössler method.24 Since Sprague Dawley rats are 
insensitive to our asthma model, guinea pigs were used 
instead in this part of the study, and those guinea pigs with 
an asthma latent period exceeding 120 seconds were not 
included. Three groups of guinea pigs (n = 6 per group) given 
SBS liposomes, free SBS solution, or saline were observed 
for anti-asthmatic effect after spraying of histamine. 
  Histamine is known to play an important role in bronchi 
constriction mediated by histamine receptors causing bron-
chial asthma attack39 and was used to induce asthma in our 
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guinea pig model. An anti-asthmatic effect was considered 
to be present when the animal did not twitch and fall down 
for at least 15 minutes (asthma latent period) after histamine 
treatment. The two groups of guinea pigs treated with SBS 
liposome suspension or free SBS solution displayed the anti-
asthmatic effect, whereas no anti-asthmatic effects were 
observed for the saline blank group (Figure 5). The SBS 
liposome group showed an apparent anti-asthmatic effect for 
up to 18 hours after pulmonary administration. In contrast, 
the free SBS solution group maintained the anti-asthmatic 
effect for only up to 6 hours. At 8 hours after pulmonary 
administration, the free SBS solution group was found to 
twitch and fall down as a result of histamine treatment, and 
the asthma latent period was 134 ± 27 seconds (compared to 
98.3 ± 18 seconds for the saline blank group, P , 0.05), 
indicating that the anti-asthmatic effect of free SBS solution 
had ceased by that time point. These pharmacodynamic data 
were found to correspond with the time-dependent concentra-
tions of liposomal SBS or free SBS observed in rat lungs 
after pulmonary delivery (Figure 4), showing that the anti-
asthmatic effect of entrapped SBS was correlated with reten-
tion of SBS by liposomes in the lungs. Moreover, our guinea 
pig model displayed rapid and persistent acting of SBS lipo-
somes for the treatment of acute asthma. Taking all the in 
vivo data into consideration, it can be concluded that lipo-
some formulation may allow localization of SBS in the 
pulmonary tissues contributing to sustained release of SBS 
and thus exerting a prolonged anti-asthmatic effect.
Conclusion
Liposomes showed promising properties as a drug delivery 
system for SBS. Water-soluble SBS could be efficiently 
encapsulated into liposomes prepared by the VPG method. 
The optimal EE was achieved by use of isotonic agents. In 
addition to the sustained release effect of the formulation, 
unencapsulated SBS in the liposome suspension may pro-
vide an immediate bronchodilating effect. In vivo animal 
studies showed that SBS was released from liposomes to 
act on the β2 receptor in the pulmonary tissues leading to 
the bronchodilating effect. Fluorescence images of DiR 
SBS liposomes indicated that liposomes were homoge-
neously distributed in the lungs and the total decrease of 
radiation intensity suggested that lipids and DiR itself may 
be eliminated in time from the respiratory tissues. The 
pharmacodynamic study of guinea pigs demonstrated a 
significantly longer anti-asthmatic effect by SBS liposome 
suspension compared to free SBS solution. In summary, 
the present study suggests higher therapeutic efficacy for 
SBS by liposome-mediated pulmonary delivery, as this 
approach can reduce the frequency of administration by 
increasing the drug retention time in the lungs and avoid 
systemic side effects due to accumulating drug after fre-
quent administration. Future studies may focus on the 
modification of liposomes by using polyethylene glycol to 
enhance the stability of liposomes in vivo and, furthermore, 
by conjugating with targeting ligands to enrich site-specific 
therapeutic action.
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